An anti-aging drug today: from senescence-promoting genes to anti-aging pill

Area of Science:

• Gerontology
• Pharmacology
• Molecular Biology

Background:

• Mutations affecting lifespan are common across diverse organisms, from simple invertebrates to mammals.
• Many longevity-associated genes are components of the target of rapamycin (TOR) pathway, suggesting it as a key regulator of aging.
• The TOR pathway's central role in aging presents opportunities for pharmacological intervention.

Purpose of the Study:

• To highlight the target of rapamycin (TOR) pathway as a primary target for anti-aging interventions.
• To evaluate rapamycin, a TOR inhibitor, as a potential therapeutic agent for age-related diseases.
• To discuss other anti-aging agents and their relationship with the TOR pathway.

Main Methods:

• Review of preclinical and clinical data on rapamycin's effects on aging and age-related diseases.
• Analysis of the molecular targets and mechanisms of action for various anti-aging agents.
• Exploration of potential synergistic effects between different anti-aging strategies.

Main Results:

• Rapamycin is a non-toxic, orally administered drug with demonstrated efficacy in preclinical and clinical studies for age-related conditions.
• Rapamycin exhibits beneficial "side-effects" including anti-tumor, bone-sparing, and calorie-restriction-mimicking properties.
• Other agents like metformin, resveratrol, and sirtuins also impact aging, with potential interactions with the TOR pathway.

Conclusions:

• Rapamycin is a highly promising candidate for pharmacological intervention against age-related diseases due to its safety profile and multifaceted benefits.
• Understanding the interplay between the TOR pathway and other aging pathways is crucial for developing effective combination therapies.
• Further research into combining rapamycin with other agents, including antioxidants, may yield enhanced anti-aging effects.